English Ukrainian
Clinical medicine

CLINICAL SIGNIFICANCE OF B-CELL ACTIVATING FACTOR BAFF IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Published 2025-03-12

Authors:

R.M. Mirjavadli
Abstract:
The study involved 17 children with systemic lupus erythematosus receiving treatment at the Educational Therapeutic Clinic of Azerbaijan Medical University. The mean age was 15.7±0.5 years. In all patients amount of B-cell activating factor–BAFF, anti nuclear antibodies, anti-double-stranded deoxyribonucleic acid and single-stranded deoxyribonucleic acid antibodies, IgA, IgM, IgG, IgE, circulating immune complexes in serum were determined. The disease activity level was calculated according to the SLEDAI–2k scale. The amount of BAFF increased in SLE patients, and more so in patients with high activity compared with patients with moderate activity (6.6 ng/ml and 4.3 ng/ml, respectively). There is a positive reliable relationship between BAFF and the circulating immune complexes (ρ=0.829; p=0.021), anti-double-stranded deoxyribonucleic acid antibodies (ρ=0.854; p=0.003) and the SLEDAI–2k index (ρ=0.613; p=0.009). The development and improvement of anti-BAFF therapy in children may be considered more appropriate than the conventional therapy used.
Keywords:
systemic lupus erythematosus B-lymphocytes BAFF circulating immune complexes SLEDAI–2k scale
References:
  1. Ceccarelli F, Perricone C, Massaro L, Cipriano E, Alessandri C, Spinelli FR, et al. Assessment of disease activity in Systemic Lupus Erythematosus: Lights and shadows. Autoimmun Rev. 2015 Jul;14(7):601-8. doi: 10.1016/j.autrev.2015.02.008.
  2. Friebus-Kardash J, Trendelenburg M, Eisenberger U, Ribi C, Chizzolini C, Huynh-Do U, et al. Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis. BMC Nephrol. 2019 Nov 21;20(1):430. doi: 10.1186/s12882-019-1623-4.
  3. Harry O, Yasin S, Brunner H. Childhood-Onset Systemic Lupus Erythematosus: A Review and Update. J Pediatr. 2018 May; 196:22-30.e2. doi: 10.1016/j.jpeds.2018.01.045.
  4. Lu W, Zhong Y, Weng C, Wang Q, Tang M, Liu Z, et al. Utility of the ACR-1997, SLICC-2012 and EULAR/ACR-2019 classification criteria for systemic lupus erythematosus: a single-centre retrospective study. Lupus Sci Med. 2022 Sep 7;9(1):e000718. doi: 10.1136/lupus-2022-000718.
  5. Marín-Rosales M, Cruz A, Salazar-Camarena DC, Santillán-López E, Espinoza-García N, Muñoz-Valle JF, et al. High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C>T polymorphism in TNFSF13B gene. Clin Exp Med. 2019 May;19(2):183-190. doi: 10.1007/s10238-019-00549-8.
  6. Mercado U, Díaz-Molina R. Nivel de estimulador de linfocitos B (BLyS/BAFF) en el suero de pacientes con lupus [B lymphocyte stimulator (BLyS/BAFF) level in sera of patients with lupus]. Rev Med Inst Mex Seguro Soc. 2016 May-Jun;54(3):334-7. PMID: 27100979. [In Spanish].
  7. Möckel T, Basta F, Weinmann-Menke J, Schdwarting A. B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev. 2021 Feb;20(2):102736. doi: 10.1016/j.autrev.2020.102736.
  8. Rezazadeh M, Jokar MH, Mehrnaz Aghili S, Mirfeizi Z, Mahmoudi M, Morovatdar N, et al. Association between levels of serum and urinary B cell-activating factor and systemic lupus erythematosus disease activity. Arch Rheumatol. 2023 Jun 14;38(3):429-440. doi: 10.46497/ArchRheumatol.2023.9549.
  9. Salazar-Camarena DC, Ortíz-Lazareno P, Marín-Rosales M, Cruz A, Muñoz-Valle F, Tapia-Llanos R, et al. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus. Cytokine. 2019 Feb;114:115-127. doi: 10.1016/j.cyto.2018.11.008.
  10. Sarı S, İnanç M. BLyS (BAFF) and APRIL in the pathogenesis of systemic lupus erythematosus. J Turk Soc Rheumatol. 2019 Dec;11(2):110-116. doi:10.2399/raed.19.43434.
  11. Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016 Nov 22;12(12):716-730. doi: 10.1038/nrrheum.2016.186.
  12. Vitri RY, Wachjudi RG, Ghassani NG, Hamijoyo L. Correlation of B-Cell-Activating Factor Levels and Diseases Activity in Systemic Lupus Erythematosus Patients. Indian Journal of Rheumatology 16(1):p 13-17, March 2021. doi: 10.4103/injr.injr_122_20.
Publication:
«World of Medicine and Biology» Vol. 21 No. 91 (2025) , с. 77-81
УДК 616.5-002.525.2
DOI:
https://doi.org/10.26724/2079-8334-2025-1-91-77-81